Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00824-23 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Amer El Ghali und 32 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Mycobacterium Infections, Nontuberculous, Cystic Fibrosis, Mycobacterium abscessus. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NCEZID CDC HHS.
Abstract (Originalsprache)
Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including Mycobacteroides abscessus (MAB). This multicenter retrospective study across 16 U.S. medical institutions from January 2020 to March 2023 examined the long-term clinical success, safety, and tolerability of OMC for NTM infections. The cohort included patients aged ≥18 yr, who were clinically evaluable, and` had been treated with OMC for ≥3 mo without a previous diagnosis of cystic fibrosis. The primary outcome was 3 mo clinical success, with secondary outcomes including clinical improvement and mortality at 6- and 12 mo, persistence or reemergence of infection, adverse effects, and reasons for OMC utilization. Seventy-five patients were included in this analysis. Most patients were female (48/75, 64.0%) or Caucasian (58/75, 77.3%), with a median (IQR) age of 59 yr (49–67). Most had NTM pulmonary disease (33/75, 44.0%), skin and soft tissue disease (19/75, 25.3%), or osteomyelitis (10/75, 13.3%), and Mycobacterium abscessus (60/75, 80%) was the most commonly isolated NTM pathogen. The median (IQR) treatment duration was 6 mo ( 4 – 14 ), and the most commonly co-administered antibiotic was azithromycin (33/70, 47.1%). Three-month clinical success was observed in 80.0% (60/75) of patients, and AEs attributable to OMC occurred in 32.0% (24/75) of patients, leading to drug discontinuation in 9.3% (7/75).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit, Michigan, USA.
- Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy , Charleston, South Carolina, USA.
- Department of Pharmacy Services, Medical University of South Carolina (MUSC) Health , Charleston, South Carolina, USA.
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Miller School of Medicine, University of Miami , Miami, Florida, USA.
- University of Texas Health Science Center, University of Texas , Tyler, Texas, USA.
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
ORCID-Profile: Amer El Ghali, Michael J Rybak
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NCEZID CDC HHS
- Paratek Pharmaceuticals
Zitieren
APA
El Ghali, A., Morrisette, T., Alosaimy, S., Lucas, K., Tupayachi-Ortiz, M. G., Vemula, R., Wadle, C., Philley, J. V., Mejia-Chew, C., Hamad, Y., Stevens, R. W., Zeuli, J. D., Webb, A. J., Fiske, C. T., Simonyan, A., Cimino, C. L., Mammadova, M., Umana, V. E., Hasbun, R., …, & Rybak, M. J. (2023). Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00824-23
Vancouver
El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00824-23
BibTeX
@article{ElGhali2023,
author = {El Ghali, Amer and Morrisette, Taylor and Alosaimy, Sara and Lucas, Kristen and Tupayachi-Ortiz, Maria G and Vemula, Raaga and Wadle, Carly and Philley, Julie V and Mejia-Chew, Carlos and Hamad, Yasir and Stevens, Ryan W and Zeuli, John D and Webb, Andrew J and Fiske, Christina T and Simonyan, Anahit and Cimino, Christo L and Mammadova, Mehriban and Umana, Virginia E and Hasbun, Rodrigo and Butt, Saira and Molina, Kyle C and Thomas, Michael and Kaip, Emily A and Bouchard, Jeannette and Gore, Tristan W and Howard, Catessa and Cabanilla, M Gabriela and Holger, Dana J and Frens, Jeremy J and Barger, Melissa and Ong, Aaron and Cohen, Keira A and Rybak, Michael J},
title = {Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00824-23}
}
EUVIMED